Exosome Diagnostic and Therapeutic Market By Application (Diagnostic, Therapeutic), By Product (Instrument, Reagent, Software), By End User (Cancer Institute, Hospital, Diagnostic Center, Others): Global Opportunity Analysis and Industry Forecast, 2020-2030

Exosome Diagnostic and Therapeutic Market

Exosome diagnostic and therapeutic products are the medical instruments, which imply in the exosome-based research activities, used primarily in the investigation of various diseases, such as cancer and cardiac diseases, and others. The adoption of exosome instruments is increased among the healthcare and research professionals. The healthcare and research professionals provide immediate direction for the accurate diagnosis of diseases. In addition, technological advancements in the exosome isolation instruments attract end users to adopt the instruments for the isolation of micro and nanovesicle from the various types of body fluids.

Major factors that boost the global exosome diagnostic and therapeutic market growth include increase in incidence of cancer, chronic, and infectious disease; growth in investments in R&D activities in exosome diagnostic and therapeutic industry; and surge in initiatives implemented by the government and non-government associations for healthcare development. In addition, technological advancements for easy exosome isolation and advancement in applications of exosome support the growth of the exosome diagnostic and therapeutic industry. In addition, the developing countries, such as China and India are expected to provide huge growth opportunities to the market. However, stringent government regulations for the approval of exosome diagnostic and therapeutic products and ack of awareness about the applications of exosome in developing countries restrict the market growth. The exosome diagnostic and therapeutic market analysis is segmented on the basis of application, product, end user, and region. On the basis of application, it is divided into diagnostic application and therapeutic application. Increase in demand for exosome as a biomarker in the diagnosis of cancer, surge in prevalence of cancer with rise in geriatric population, and growth in sedentary lifestyle are the major factors that contribute toward the growth of the exosome diagnostic market, and exosome therapeutic market.

Depending on product, the reagent segment held the largest market share in 2020, owing to its frequent use in healthcare facilities for the isolation of exosome and research procedures. However, the reagents segment is expected to witness considerable growth during the forecast period, owing to increase in need for molecular diagnosis and surge in R&D activities for the purpose of diagnosis. As per the end user, the diagnostic segment held the largest share of 30.3%.

Region wise, North American accounted 28.6% of the share in the  market from 2021 to 2030, and is expected to maintain this leading position throughout the forecast period. The growth in the exosome diagnostic and therapeutic market in the region is attributed to the technological advancement in the isolation of exosomes, innovative and advanced applications of exosome-based products, and geriatric population coupled with increasing incidence of diseases, such as cancer and cardiovascular diseases. However, Asia-Pacific is projected to be the fastest-growing region, registering a CAGR of 30.3% during the exosome diagnostic and therapeutic market forecast period. This is mainly due to  increase in awareness of innovative and advanced applications of exosome-based diagnostic and therapeutic products. In addition, increase in research outsourcing from emerging markets, rise in improvement of healthcare infrastructures, and surge in expenditures in the developing markets, such as India and China to overcome the unmet medical needs in these countries boost the market growth.

COVID-19 positively impacted the exosome diagnostic and therapeutic market share, due to rise in number of infectious disease cases, surge in availability of healthcare services in developing countries, and increase in demand for exosome diagnostic & therapeutic technology. Driving factors of the exosome diagnostic and therapeutic market are improvement in precision and surge in advantages over traditional methods of diagnosis and therapeutics.  

KEY FINDINGS OF THE STUDY

By product type, the reagent segment was the highest contributor to the market in 2020.

By application, the diagnostic segment was the highest contributor to the market in 2020.

By end user, the cancer institute segment was the highest contributor to the market in 2020.

Region wise, North American region garnered the largest revenue share in 2020; however, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.

Overview

The global exosome diagnostic and therapeutic market was valued at $224.3 million in 2020, and is projected to reach $2,928.8 million by 2030, registering a CAGR of 29.4% from 2021 to 2030. Exosomes are small extracellular vesicles present in various body fluids, such as saliva, urine, blood, and breast milk. These vesicles play an important role in intercellular communication processes and have specific composition of proteins, lipids, messenger ribonucleic acid (mRNA), and micro ribonucleic acid (RNA). Presently, exosomes have great potential to be utilized for drug delivery and a biomarker for the diagnosis and testing of various diseases. Moreover, exosomes offer an alternative pathway for invasive biopsy used in the diagnosis and management of different types of cancer. The global exosome diagnostic and therapeutic market is driven by increase in prevalence of cancer, growth in initiatives implemented by the government and non-government associations, rise in health awareness, technological advancements in exosomes isolation, surge in analytical procedures, and increase in innovative and advanced applications of exosomes. However, stringent government regulations for the approval of exosomes diagnostic and therapeutic products and lack of  awareness about the applications of exosomes restrict the market growth.

Furthermore, the developing countries, such as China and India are expected to provide huge growth opportunities to this market. The exosomes diagnostic and therapeutic market is segmented on the basis of application, product, end user, and region. As per the application, it is bifurcated into diagnostic and therapeutic applications. By the product, it is classified into instrument, reagents, and software. Depending on end user, it is segmented into cancer institute, hospitals, diagnostic centers, and others (medical universities and not-for-profit organizations). Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America dominated the market in 2020, and is expected to maintain its dominance throughout the forecast period, due to factors, such as increase in R&D investments, technological advancement in the exosomes isolation procedures, and rise in incidence of cancer. In addition, Asia-Pacific is expected to emerge as the area with maximum growth potential due to the increase in focus of key players on developing countries, rise in clinical research & trial outsourcing, growth in awareness & focus on health of the people, and surge in incidence of cancer & other chronic diseases.

 The report provides a comprehensive analysis of the key players operating in the exosome diagnostics and therapeutic market, including Aethlon Medical, Inc. (U.S.), Exosome Diagnostics Inc. (U.S.), NanoSomix Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Malvern Instruments Ltd. (UK), System Biosciences Inc. (U.S.), NX Pharmagen (U.S.), Sistemic Inc. (UK), Capricor Therapeutics (U.S.), and Exiqon A/S (Denmark).

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the exosome diagnostic and therapeutic market analysis from 2020 to 2030 to identify the prevailing exosome diagnostic and therapeutic market opportunity.

The market research is offered along with information related to key drivers, restraints, and opportunities.

Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

In-depth analysis of the exosome diagnostic and therapeutic market segmentation assists to determine the prevailing market opportunities.

Major countries in each region are mapped according to their revenue contribution to the global market.

Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

The report includes the analysis of the regional as well as global exosome diagnostic and therapeutic market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

Exiqon A/

Scope of Exosome Diagnostic and Therapeutic Market Report

1.1.Report description

1.2.Key market segments

1.3.Key benefits to the stakeholders

1.4.Research Methodology

1.4.1.Secondary research

1.4.2.Primary research

1.4.3.Analyst tools and models

2.1.Key findings of the study

2.2.CXO Perspective

3.1.Market definition and scope

3.2.Key findings

3.2.1.Top investment pockets

3.3.Porter’s five forces analysis

3.4.Top player positioning

3.5.Market dynamics

3.5.1.Drivers

3.5.2.Restraints

3.5.3.Opportunities

3.6.COVID-19 Impact Analysis on the market

4.1 Overview

4.1.1 Market size and forecast

4.2 Diagnostic

4.2.1 Key market trends, growth factors and opportunities

4.2.2 Market size and forecast, by region

4.2.3 Market analysis by country

4.3 Therapeutic

4.3.1 Key market trends, growth factors and opportunities

4.3.2 Market size and forecast, by region

4.3.3 Market analysis by country

5.1 Overview

5.1.1 Market size and forecast

5.2 Instrument

5.2.1 Key market trends, growth factors and opportunities

5.2.2 Market size and forecast, by region

5.2.3 Market analysis by country

5.3 Reagent

5.3.1 Key market trends, growth factors and opportunities

5.3.2 Market size and forecast, by region

5.3.3 Market analysis by country

5.4 Software

5.4.1 Key market trends, growth factors and opportunities

5.4.2 Market size and forecast, by region

5.4.3 Market analysis by country

6.1 Overview

6.1.1 Market size and forecast

6.2 Cancer Institute

6.2.1 Key market trends, growth factors and opportunities

6.2.2 Market size and forecast, by region

6.2.3 Market analysis by country

6.3 Hospital

6.3.1 Key market trends, growth factors and opportunities

6.3.2 Market size and forecast, by region

6.3.3 Market analysis by country

6.4 Diagnostic Center

6.4.1 Key market trends, growth factors and opportunities

6.4.2 Market size and forecast, by region

6.4.3 Market analysis by country

6.5 Others

6.5.1 Key market trends, growth factors and opportunities

6.5.2 Market size and forecast, by region

6.5.3 Market analysis by country

7.1 Overview

7.1.1 Market size and forecast

7.2 North America

7.2.1 Key trends and opportunities

7.2.2 North America Market size and forecast, by Application

7.2.3 North America Market size and forecast, by Product

7.2.4 North America Market size and forecast, by End User

7.2.5 North America Market size and forecast, by country

7.2.5.1 U.S.

7.2.5.1.1 Market size and forecast, by Application

7.2.5.1.2 Market size and forecast, by Product

7.2.5.1.3 Market size and forecast, by End User

7.2.5.2 Canada

7.2.5.2.1 Market size and forecast, by Application

7.2.5.2.2 Market size and forecast, by Product

7.2.5.2.3 Market size and forecast, by End User

7.2.5.3 Mexico

7.2.5.3.1 Market size and forecast, by Application

7.2.5.3.2 Market size and forecast, by Product

7.2.5.3.3 Market size and forecast, by End User

7.3 Europe

7.3.1 Key trends and opportunities

7.3.2 Europe Market size and forecast, by Application

7.3.3 Europe Market size and forecast, by Product

7.3.4 Europe Market size and forecast, by End User

7.3.5 Europe Market size and forecast, by country

7.3.5.1 Germany

7.3.5.1.1 Market size and forecast, by Application

7.3.5.1.2 Market size and forecast, by Product

7.3.5.1.3 Market size and forecast, by End User

7.3.5.2 France

7.3.5.2.1 Market size and forecast, by Application

7.3.5.2.2 Market size and forecast, by Product

7.3.5.2.3 Market size and forecast, by End User

7.3.5.3 U.K.

7.3.5.3.1 Market size and forecast, by Application

7.3.5.3.2 Market size and forecast, by Product

7.3.5.3.3 Market size and forecast, by End User

7.3.5.4 Italy

7.3.5.4.1 Market size and forecast, by Application

7.3.5.4.2 Market size and forecast, by Product

7.3.5.4.3 Market size and forecast, by End User

7.3.5.5 Spain

7.3.5.5.1 Market size and forecast, by Application

7.3.5.5.2 Market size and forecast, by Product

7.3.5.5.3 Market size and forecast, by End User

7.3.5.6 Rest of Europe

7.3.5.6.1 Market size and forecast, by Application

7.3.5.6.2 Market size and forecast, by Product

7.3.5.6.3 Market size and forecast, by End User

7.4 Asia-Pacific

7.4.1 Key trends and opportunities

7.4.2 Asia-Pacific Market size and forecast, by Application

7.4.3 Asia-Pacific Market size and forecast, by Product

7.4.4 Asia-Pacific Market size and forecast, by End User

7.4.5 Asia-Pacific Market size and forecast, by country

7.4.5.1 Japan

7.4.5.1.1 Market size and forecast, by Application

7.4.5.1.2 Market size and forecast, by Product

7.4.5.1.3 Market size and forecast, by End User

7.4.5.2 China

7.4.5.2.1 Market size and forecast, by Application

7.4.5.2.2 Market size and forecast, by Product

7.4.5.2.3 Market size and forecast, by End User

7.4.5.3 Rest of Asia-Pacific

7.4.5.3.1 Market size and forecast, by Application

7.4.5.3.2 Market size and forecast, by Product

7.4.5.3.3 Market size and forecast, by End User

7.5 LAMEA

7.5.1 Key trends and opportunities

7.5.2 LAMEA Market size and forecast, by Application

7.5.3 LAMEA Market size and forecast, by Product

7.5.4 LAMEA Market size and forecast, by End User

7.5.5 LAMEA Market size and forecast, by country

7.5.5.1 Brazil

7.5.5.1.1 Market size and forecast, by Application

7.5.5.1.2 Market size and forecast, by Product

7.5.5.1.3 Market size and forecast, by End User

7.5.5.2 Saudi Arabia

7.5.5.2.1 Market size and forecast, by Application

7.5.5.2.2 Market size and forecast, by Product

7.5.5.2.3 Market size and forecast, by End User

7.5.5.3 South Africa

7.5.5.3.1 Market size and forecast, by Application

7.5.5.3.2 Market size and forecast, by Product

7.5.5.3.3 Market size and forecast, by End User

7.5.5.4 Rest of LAMEA

7.5.5.4.1 Market size and forecast, by Application

7.5.5.4.2 Market size and forecast, by Product

7.5.5.4.3 Market size and forecast, by End User

8.1. Introduction

8.2. Top winning strategies

8.3. Product Mapping of Top 10 Player

8.4. Competitive Dashboard

8.5. Competitive Heatmap

8.6. Key developments

9.1 Aethlon Medical, Inc.

9.1.1 Company overview

9.1.2 Company snapshot

9.1.3 Operating business segments

9.1.4 Product portfolio

9.1.5 Business performance

9.1.6 Key strategic moves and developments

9.2 Exosome Diagnostic, Inc.

9.2.1 Company overview

9.2.2 Company snapshot

9.2.3 Operating business segments

9.2.4 Product portfolio

9.2.5 Business performance

9.2.6 Key strategic moves and developments

9.3 NanoSomix, Inc

9.3.1 Company overview

9.3.2 Company snapshot

9.3.3 Operating business segments

9.3.4 Product portfolio

9.3.5 Business performance

9.3.6 Key strategic moves and developments

9.4 Thermo Fisher Scientific, Inc.

9.4.1 Company overview

9.4.2 Company snapshot

9.4.3 Operating business segments

9.4.4 Product portfolio

9.4.5 Business performance

9.4.6 Key strategic moves and developments

9.5 Malvern Instruments Ltd

9.5.1 Company overview

9.5.2 Company snapshot

9.5.3 Operating business segments

9.5.4 Product portfolio

9.5.5 Business performance

9.5.6 Key strategic moves and developments

9.6 System Biosciences, Inc

9.6.1 Company overview

9.6.2 Company snapshot

9.6.3 Operating business segments

9.6.4 Product portfolio

9.6.5 Business performance

9.6.6 Key strategic moves and developments

9.7 NX Pharmagen

9.7.1 Company overview

9.7.2 Company snapshot

9.7.3 Operating business segments

9.7.4 Product portfolio

9.7.5 Business performance

9.7.6 Key strategic moves and developments

9.8 Sistemic Ltd

9.8.1 Company overview

9.8.2 Company snapshot

9.8.3 Operating business segments

9.8.4 Product portfolio

9.8.5 Business performance

9.8.6 Key strategic moves and developments

9.9 Capricor Therapeutics, Inc.

9.9.1 Company overview

9.9.2 Company snapshot

9.9.3 Operating business segments

9.9.4 Product portfolio

9.9.5 Business performance

9.9.6 Key strategic moves and developments

9.10 Exiqon A/S

9.10.1 Company overview

9.10.2 Company snapshot

9.10.3 Operating business segments

9.10.4 Product portfolio

9.10.5 Business performance

9.10.6 Key strategic moves and development

LIST OF TABLES

TABLE 1. GLOBAL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030,($MILLION)

TABLE 2. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET REVENUE, FOR DIAGNOSTIC, BY REGION , 2020-2030,($MILLION)

TABLE 3. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET DIAGNOSTIC BY COUNTRY, 2020-2030,($MILLION)

TABLE 4. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET REVENUE, FOR THERAPEUTIC, BY REGION , 2020-2030,($MILLION)

TABLE 5. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET THERAPEUTIC BY COUNTRY, 2020-2030,($MILLION)

TABLE 6. GLOBAL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030,($MILLION)

TABLE 7. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET REVENUE, FOR INSTRUMENT, BY REGION , 2020-2030,($MILLION)

TABLE 8. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET INSTRUMENT BY COUNTRY, 2020-2030,($MILLION)

TABLE 9. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET REVENUE, FOR REAGENT, BY REGION , 2020-2030,($MILLION)

TABLE 10. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET REAGENT BY COUNTRY, 2020-2030,($MILLION)

TABLE 11. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET REVENUE, FOR SOFTWARE, BY REGION , 2020-2030,($MILLION)

TABLE 12. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET SOFTWARE BY COUNTRY, 2020-2030,($MILLION)

TABLE 13. GLOBAL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030,($MILLION)

TABLE 14. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET REVENUE, FOR CANCER INSTITUTE, BY REGION , 2020-2030,($MILLION)

TABLE 15. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET CANCER INSTITUTE BY COUNTRY, 2020-2030,($MILLION)

TABLE 16. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET REVENUE, FOR HOSPITAL, BY REGION , 2020-2030,($MILLION)

TABLE 17. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET HOSPITAL BY COUNTRY, 2020-2030,($MILLION)

TABLE 18. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET REVENUE, FOR DIAGNOSTIC CENTER, BY REGION , 2020-2030,($MILLION)

TABLE 19. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET DIAGNOSTIC CENTER BY COUNTRY, 2020-2030,($MILLION)

TABLE 20. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET REVENUE, FOR OTHERS, BY REGION , 2020-2030,($MILLION)

TABLE 21. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET OTHERS BY COUNTRY, 2020-2030,($MILLION)

TABLE 22. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY REGION, 2020-2030,($MILLION)

TABLE 23. NORTH AMERICA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030,($MILLION)

TABLE 24. NORTH AMERICA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030,($MILLION)

TABLE 25. NORTH AMERICA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030,($MILLION)

TABLE 26. NORTH AMERICA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY COUNTRY, 2020-2030,($MILLION)

TABLE 27. U.S. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY APPLICATION 2020-2030,($MILLION)

TABLE 28. U.S. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY PRODUCT 2020-2030,($MILLION)

TABLE 29. U.S. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY END USER 2020-2030,($MILLION)

TABLE 30. CANADA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY APPLICATION 2020-2030,($MILLION)

TABLE 31. CANADA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY PRODUCT 2020-2030,($MILLION)

TABLE 32. CANADA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY END USER 2020-2030,($MILLION)

TABLE 33. MEXICO EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY APPLICATION 2020-2030,($MILLION)

TABLE 34. MEXICO EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY PRODUCT 2020-2030,($MILLION)

TABLE 35. MEXICO EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY END USER 2020-2030,($MILLION)

TABLE 36. EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030,($MILLION)

TABLE 37. EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030,($MILLION)

TABLE 38. EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030,($MILLION)

TABLE 39. EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY COUNTRY, 2020-2030,($MILLION)

TABLE 40. GERMANY EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY APPLICATION 2020-2030,($MILLION)

TABLE 41. GERMANY EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY PRODUCT 2020-2030,($MILLION)

TABLE 42. GERMANY EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY END USER 2020-2030,($MILLION)

TABLE 43. FRANCE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY APPLICATION 2020-2030,($MILLION)

TABLE 44. FRANCE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY PRODUCT 2020-2030,($MILLION)

TABLE 45. FRANCE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY END USER 2020-2030,($MILLION)

TABLE 46. U.K. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY APPLICATION 2020-2030,($MILLION)

TABLE 47. U.K. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY PRODUCT 2020-2030,($MILLION)

TABLE 48. U.K. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY END USER 2020-2030,($MILLION)

TABLE 49. ITALY EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY APPLICATION 2020-2030,($MILLION)

TABLE 50. ITALY EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY PRODUCT 2020-2030,($MILLION)

TABLE 51. ITALY EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY END USER 2020-2030,($MILLION)

TABLE 52. SPAIN EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY APPLICATION 2020-2030,($MILLION)

TABLE 53. SPAIN EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY PRODUCT 2020-2030,($MILLION)

TABLE 54. SPAIN EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY END USER 2020-2030,($MILLION)

TABLE 55. REST OF EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY APPLICATION 2020-2030,($MILLION)

TABLE 56. REST OF EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY PRODUCT 2020-2030,($MILLION)

TABLE 57. REST OF EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY END USER 2020-2030,($MILLION)

TABLE 58. ASIA-PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030,($MILLION)

TABLE 59. ASIA-PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030,($MILLION)

TABLE 60. ASIA-PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030,($MILLION)

TABLE 61. ASIA-PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY COUNTRY, 2020-2030,($MILLION)

TABLE 62. JAPAN EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY APPLICATION 2020-2030,($MILLION)

TABLE 63. JAPAN EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY PRODUCT 2020-2030,($MILLION)

TABLE 64. JAPAN EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY END USER 2020-2030,($MILLION)

TABLE 65. CHINA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY APPLICATION 2020-2030,($MILLION)

TABLE 66. CHINA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY PRODUCT 2020-2030,($MILLION)

TABLE 67. CHINA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY END USER 2020-2030,($MILLION)

TABLE 68. REST OF ASIA-PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY APPLICATION 2020-2030,($MILLION)

TABLE 69. REST OF ASIA-PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY PRODUCT 2020-2030,($MILLION)

TABLE 70. REST OF ASIA-PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY END USER 2020-2030,($MILLION)

TABLE 71. LAMEA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030,($MILLION)

TABLE 72. LAMEA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030,($MILLION)

TABLE 73. LAMEA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030,($MILLION)

TABLE 74. LAMEA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY COUNTRY, 2020-2030,($MILLION)

TABLE 75. BRAZIL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY APPLICATION 2020-2030,($MILLION)

TABLE 76. BRAZIL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY PRODUCT 2020-2030,($MILLION)

TABLE 77. BRAZIL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY END USER 2020-2030,($MILLION)

TABLE 78. SAUDI ARABIA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY APPLICATION 2020-2030,($MILLION)

TABLE 79. SAUDI ARABIA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY PRODUCT 2020-2030,($MILLION)

TABLE 80. SAUDI ARABIA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY END USER 2020-2030,($MILLION)

TABLE 81. SOUTH AFRICA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY APPLICATION 2020-2030,($MILLION)

TABLE 82. SOUTH AFRICA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY PRODUCT 2020-2030,($MILLION)

TABLE 83. SOUTH AFRICA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY END USER 2020-2030,($MILLION)

TABLE 84. REST OF LAMEA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY APPLICATION 2020-2030,($MILLION)

TABLE 85. REST OF LAMEA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY PRODUCT 2020-2030,($MILLION)

TABLE 86. REST OF LAMEA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY END USER 2020-2030,($MILLION)

TABLE 87.AETHLON MEDICAL, INC.: COMPANY SNAPSHOT

TABLE 88.AETHLON MEDICAL, INC.: OPERATING SEGMENTS

TABLE 89.AETHLON MEDICAL, INC.: PRODUCT PORTFOLIO

TABLE 90.AETHLON MEDICAL, INC.: NET SALES,

TABLE 91.AETHLON MEDICAL, INC.: KEY STRATERGIES

TABLE 92.EXOSOME DIAGNOSTIC, INC.: COMPANY SNAPSHOT

TABLE 93.EXOSOME DIAGNOSTIC, INC.: OPERATING SEGMENTS

TABLE 94.EXOSOME DIAGNOSTIC, INC.: PRODUCT PORTFOLIO

TABLE 95.EXOSOME DIAGNOSTIC, INC.: NET SALES,

TABLE 96.EXOSOME DIAGNOSTIC, INC.: KEY STRATERGIES

TABLE 97.NANOSOMIX, INC: COMPANY SNAPSHOT

TABLE 98.NANOSOMIX, INC: OPERATING SEGMENTS

TABLE 99.NANOSOMIX, INC: PRODUCT PORTFOLIO

TABLE 100.NANOSOMIX, INC: NET SALES,

TABLE 101.NANOSOMIX, INC: KEY STRATERGIES

TABLE 102.THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT

TABLE 103.THERMO FISHER SCIENTIFIC, INC.: OPERATING SEGMENTS

TABLE 104.THERMO FISHER SCIENTIFIC, INC.: PRODUCT PORTFOLIO

TABLE 105.THERMO FISHER SCIENTIFIC, INC.: NET SALES,

TABLE 106.THERMO FISHER SCIENTIFIC, INC.: KEY STRATERGIES

TABLE 107.MALVERN INSTRUMENTS LTD: COMPANY SNAPSHOT

TABLE 108.MALVERN INSTRUMENTS LTD: OPERATING SEGMENTS

TABLE 109.MALVERN INSTRUMENTS LTD: PRODUCT PORTFOLIO

TABLE 110.MALVERN INSTRUMENTS LTD: NET SALES,

TABLE 111.MALVERN INSTRUMENTS LTD: KEY STRATERGIES

TABLE 112.SYSTEM BIOSCIENCES, INC: COMPANY SNAPSHOT

TABLE 113.SYSTEM BIOSCIENCES, INC: OPERATING SEGMENTS

TABLE 114.SYSTEM BIOSCIENCES, INC: PRODUCT PORTFOLIO

TABLE 115.SYSTEM BIOSCIENCES, INC: NET SALES,

TABLE 116.SYSTEM BIOSCIENCES, INC: KEY STRATERGIES

TABLE 117.NX PHARMAGEN: COMPANY SNAPSHOT

TABLE 118.NX PHARMAGEN: OPERATING SEGMENTS

TABLE 119.NX PHARMAGEN: PRODUCT PORTFOLIO

TABLE 120.NX PHARMAGEN: NET SALES,

TABLE 121.NX PHARMAGEN: KEY STRATERGIES

TABLE 122.SISTEMIC LTD: COMPANY SNAPSHOT

TABLE 123.SISTEMIC LTD: OPERATING SEGMENTS

TABLE 124.SISTEMIC LTD: PRODUCT PORTFOLIO

TABLE 125.SISTEMIC LTD: NET SALES,

TABLE 126.SISTEMIC LTD: KEY STRATERGIES

TABLE 127.CAPRICOR THERAPEUTICS, INC.: COMPANY SNAPSHOT

TABLE 128.CAPRICOR THERAPEUTICS, INC.: OPERATING SEGMENTS

TABLE 129.CAPRICOR THERAPEUTICS, INC.: PRODUCT PORTFOLIO

TABLE 130.CAPRICOR THERAPEUTICS, INC.: NET SALES,

TABLE 131.CAPRICOR THERAPEUTICS, INC.: KEY STRATERGIES

TABLE 132.EXIQON A/S: COMPANY SNAPSHOT

TABLE 133.EXIQON A/S: OPERATING SEGMENTS

TABLE 134.EXIQON A/S: PRODUCT PORTFOLIO

TABLE 135.EXIQON A/S: NET SALES,

TABLE 136.EXIQON A/S: KEY STRATERGIES LIST OF FIGURES

FIGURE 1.EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET SEGMENTATION

FIGURE 2.EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030

FIGURE 3.EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030

FIGURE 4. TOP INVESTMENT POCKETS, BY REGION

FIGURE 5.PORTER FIVE-1

FIGURE 6.PORTER FIVE-2

FIGURE 7.PORTER FIVE-3

FIGURE 8.PORTER FIVE-4

FIGURE 9.PORTER FIVE-5

FIGURE 10.TOP PLAYER POSITIONING

FIGURE 11.EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 12.EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,BY APPLICATION,2020(%)

FIGURE 13.COMPARATIVE SHARE ANALYSIS OF DIAGNOSTIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030(%)

FIGURE 14.COMPARATIVE SHARE ANALYSIS OF THERAPEUTIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030(%)

FIGURE 15.EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,BY PRODUCT,2020(%)

FIGURE 16.COMPARATIVE SHARE ANALYSIS OF INSTRUMENT EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030(%)

FIGURE 17.COMPARATIVE SHARE ANALYSIS OF REAGENT EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030(%)

FIGURE 18.COMPARATIVE SHARE ANALYSIS OF SOFTWARE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030(%)

FIGURE 19.EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,BY END USER,2020(%)

FIGURE 20.COMPARATIVE SHARE ANALYSIS OF CANCER INSTITUTE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030(%)

FIGURE 21.COMPARATIVE SHARE ANALYSIS OF HOSPITAL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030(%)

FIGURE 22.COMPARATIVE SHARE ANALYSIS OF DIAGNOSTIC CENTER EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030(%)

FIGURE 23.COMPARATIVE SHARE ANALYSIS OF OTHERS EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030(%)

FIGURE 24.EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY REGION,2020

FIGURE 25.U.S. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030($MILLION)

FIGURE 26.CANADA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030($MILLION)

FIGURE 27.MEXICO EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030($MILLION)

FIGURE 28.GERMANY EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030($MILLION)

FIGURE 29.FRANCE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030($MILLION)

FIGURE 30.U.K. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030($MILLION)

FIGURE 31.ITALY EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030($MILLION)

FIGURE 32.SPAIN EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030($MILLION)

FIGURE 33.REST OF EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030($MILLION)

FIGURE 34.JAPAN EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030($MILLION)

FIGURE 35.CHINA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030($MILLION)

FIGURE 36.REST OF ASIA-PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030($MILLION)

FIGURE 37.BRAZIL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030($MILLION)

FIGURE 38.SAUDI ARABIA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030($MILLION)

FIGURE 39.SOUTH AFRICA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030($MILLION)

FIGURE 40.REST OF LAMEA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030($MILLION)

FIGURE 41. TOP WINNING STRATEGIES, BY YEAR

FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 44.PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 45.COMPETITIVE DASHBOARD

FIGURE 46.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS

FIGURE 47.AETHLON MEDICAL, INC..: NET SALES ,($MILLION)

FIGURE 48.EXOSOME DIAGNOSTIC, INC..: NET SALES ,($MILLION)

FIGURE 49.NANOSOMIX, INC.: NET SALES ,($MILLION)

FIGURE 50.THERMO FISHER SCIENTIFIC, INC..: NET SALES ,($MILLION)

FIGURE 51.MALVERN INSTRUMENTS LTD.: NET SALES ,($MILLION)

FIGURE 52.SYSTEM BIOSCIENCES, INC.: NET SALES ,($MILLION)

FIGURE 53.NX PHARMAGEN.: NET SALES ,($MILLION)

FIGURE 54.SISTEMIC LTD.: NET SALES ,($MILLION)

FIGURE 55.CAPRICOR THERAPEUTICS, INC..: NET SALES ,($MILLION)

FIGURE 56.EXIQON A/S.: NET SALES ,($MILLION